Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2013-05-03
Original SEC Filing: Click here

---

Webplus: SVA/20130503/6-K/2_EX-99.1/000.htm SEC Original: v343225_ex99-1.htm
Sinovac Reports Preliminary Top-Line Results from Phase III Clinical Trial for EV71 Vaccine Candidate Against Hand, Foot and Mouth Disease — Unblinded Phase III Preliminary Results Demonstrate Vaccine Efficacy Rate of 95.4% SVA BEIJING, March 14, 2013 /PRNewswire/ — Sinovac Biotech Ltd. ( ir@sinovac.com scarrington@theruthgroup.com aestrada@theruthgroup.com

---

---

Webplus: SVA/20130503/6-K/3_EX-99.2/000.htm SEC Original: v343225_ex99-2.htm
Sinovac Schedules Conference Call and Webcast for Fourth Quarter and Full Year Unaudited Financial Results Beijing – April 2, 2013 – Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of vaccines in China, today announced that it will release its unaudited financial results for the fourth quarter and full year ended December 31, 2012, before market on Thursday, April 18,

---

---

Webplus: SVA/20130503/6-K/4_EX-99.3/000.htm SEC Original: v343225_ex99-3.htm
Sinovac Receives Commercial Approval in Mexico for Seasonal Flu Vaccine SVA Beijing – April 18, 2013 – Sinovac Biotech Ltd. (Nasdaq: Dr. Weidong Yin, Chairman, President and CEO of Sinovac, said, “ This is a great milestone for Sinovac as we look to continue expanding our commercial efforts worldwide. We are pleased to receive approval to supply Anflu in the

---

---

Webplus: SVA/20130503/6-K/5_EX-99.4/000.htm SEC Original: v343225_ex99-4.htm
Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo – Efficacy and Safety Data for EV71 Vaccine Discussed in Presentation by Deputy Director of Jiangsu Provincial CDC Beijing – April 18, 2013 – Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of vaccines in China,announced today that Fengcai Zhu, Deputy Director of the

---

---

Webplus: SVA/20130503/6-K/6_EX-99.5/000.htm SEC Original: v343225_ex99-5.htm
Sinovac Reports Unaudited Fourth Quarter and Full Year 2012 Financial Results – Conference call scheduled for Thursday, April 18, 2013 at 8:00 AM EDT– – Sinovac Biotech Ltd. ( today its unaudited fourth quarter and full year Beijing – April 18, 2013 Financial Highlights l Total sales were $19.0 million for the fourth quarter of 2012, a decrease of 10.4%

---

---

Webplus: SVA/20130503/6-K/1/000.htm SEC Original: v343225_6k.htm

---

Company Information:

Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2013-05-03CIK: 0001084201, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
39 SHANGDI XI ROAD
BEIJING 100085